Reuters logo
5 months ago
BRIEF-Immune Pharmaceuticals reports preliminary data with bertilimumab in an open label phase 2 study
February 28, 2017 / 1:50 PM / 5 months ago

BRIEF-Immune Pharmaceuticals reports preliminary data with bertilimumab in an open label phase 2 study

1 Min Read

Feb 28 (Reuters) - Immune Pharmaceuticals Inc

* Immune Pharmaceuticals reports encouraging preliminary data with bertilimumab in an open label phase 2 study in the rare dermatological auto-immune disease, bullous pemphigoid

* Says no significant adverse events were reported.

* Immune Pharmaceuticals - based on these preliminary results, company has also submitted a request for orphan drug designation for bertilimumab in BP Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below